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Abstract
Background: The JAK2 V617F mutation in exon 14 is the most common mutation in chronic myeloproliferative neoplasms
(MPNs); deletion of the entire exon 14 is rarely detected. In our previous study of .10,000 samples from patients with
suspected MPNs tested for JAK2 mutations by reverse transcription-PCR (RT-PCR) with direct sequencing, complete deletion
of exon 14 (Dexon14) constituted ,1% of JAK2 mutations. This appears to be an alternative splicing mutation, not
detectable with DNA-based testing.
Methodology/Principal Findings: We investigated the possibility that MPN patients may express the JAK2 Dexon14 at low
levels (,15% of total transcript) not routinely detectable by RT-PCR with direct sequencing. Using a sensitive RT-PCR–based
fluorescent fragment analysis method to quantify JAK2 Dexon14 mRNA expression relative to wild-type, we tested 61
patients with confirmed MPNs, 183 with suspected MPNs (93 V617F-positive, 90 V617F-negative), and 46 healthy control
subjects. The Dexon14 variant was detected in 9 of the 61 (15%) confirmed MPN patients, accounting for 3.96% to 33.85%
(mean =12.04%) of total JAK2 transcript. This variant was also detected in 51 of the 183 patients with suspected MPNs
(27%), including 20 of the 93 (22%) with V617F (mean [range] expression =5.41% [2.13%–26.22%]) and 31 of the 90 (34%)
without V617F (mean [range] expression =3.88% [2.08%–12.22%]). Immunoprecipitation studies demonstrated that
patients expressing Dexon14 mRNA expressed a corresponding truncated JAK2 protein. The Dexon14 variant was not
detected in the 46 control subjects.
Conclusions/Significance: These data suggest that expression of the JAK2 Dexon14 splice variant, leading to a truncated
JAK2 protein, is common in patients with MPNs. This alternatively spliced transcript appears to be more frequent in MPN
patients without V617F mutation, in whom it might contribute to leukemogenesis. This mutation is missed if DNA rather
than RNA is used for testing.
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Introduction
Myeloproliferative neoplasms (MPNs) are multipotent hemato-
poietic stem cell disorders characterized by uncontrolled prolifer-
ation of maturing blood cells. Chronic myeloid leukemia (CML) is
the most common MPN, followed by polycythemia vera (PV),
essential thrombocythemia (ET), and idiopathic myelofibrosis
(IMF) [1]. Whereas CML is characterized by a readily detectable
translocation (Philadelphia chromosome), non-CML MPNs lack
recurrent chromosomal anomalies. However, a specific molecular
abnormality, the JAK2 V617F mutation, has been reported in
about 95% of PV patients, 35% to 70% of ET patients, and 50%
of IMF patients [2–4]. JAK2 exon 12 mutations, as well as other
mutations in exons 13 and 14, have been reported in rare cases of
non-CML MPDs negative for V617F [5–7].
Most testing for JAK2 mutations is performed by analyzing the
genomic DNA of the JAK2 gene. We have adapted the use of
mRNA as the basis for testing for JAK2 mutations and have shown
that RNA allows more sensitive detection of mutations than does
DNA at early stages of disease [7–9]. The use of RNA rather than
DNA provides the additional advantage of capturing abnormal-
ities in platelets and detecting alternatively spliced transcripts.
In a previous report of JAK2 mutation profiles in a series of
.10,000 patient samples, we described detection of a novel
deletion of JAK2 exon 14 (Dexon14) along with other JAK2
mutations in exons 12 through 15, using bi-directional mRNA
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12165sequencing technology [7]. The Dexon14 mutation was detected by
direct sequencing in less than 1% of patients with various types of
JAK2 mutations. However, direct sequencing is not amenable to
detecting deletions of entire exons, owingto difficulty in interpreting
results as well as the low sensitivity of this approach. Therefore, in
this study we used a sensitive RT-PCR–based assay with fluorescent
fragment analysis to explore the possibility that MPN patients may
commonly express this JAK2 mRNA splice variant at levels that
cannot be reliably detected by sequence analysis. We further sought
to determine whether patients expressing this splice variant also
express a corresponding truncated JAK2 protein.
Methods
Patients and Samples
We tested peripheral blood samples from three groups of
patients in addition to healthy normal control subjects. Group 1
comprised 61 consecutive randomly selected patients with
confirmed non-CML MPN on the basis of clinical findings and
complete peripheral blood and bone marrow analysis. The
diagnosis of these patients was myelofibrosis in 27 (43%),
polycythemia vera in 12 (19%), essential thrombocythemia in 6
(10%) and not-otherwise classified in 16 (27%). The other 2 patient
groups were constructed from 183 residual de-identified samples
from individuals with suspected non-CML MPNs initially
submitted to Quest Diagnostics Nichols Institute for testing of
JAK2 V617F as well as mutations in JAK2 exons 12 and 13: Group
2 comprised 90 samples that were negative for JAK2 mutations in
V617 and exon 12 and 13, and group 3 comprised 93 samples
from patients with JAK2 V617F. In addition, we tested 46 normal
healthy control individuals.
Plasma was separated from peripheral blood samples and used
for extraction of total RNA. The mRNA was then used for
detection of the JAK2 Dexon14 variant by RT-PCR with
bidirectional sequencing. All samples were also screened for the
Dexon14 transcript using a sensitive assay based on RT-PCR with
fluorescent fragment analysis.
Ethics statement
All work was performed according to a protocol approved by an
Institutional Review Board (IRB) (Independent Review Consulting
Inc. San Anselmo, California). Samples collected from group 1
and the normal control were collected with consent form.
Sequence Analysis
Total nucleic acid was extracted from patient plasma or PB/BM
cells using the NucliSens (BioMerieux, Durham, NC) extraction
kit. The primer pair was designed to encompass JAK2 exons 12
through 14 and part of exon 15: 59-CTAAATGCTGTCCCC-
CAAAG-39 (forward); and 5 9-CCATGCCAACTGTTTAGCAA-
39 (reverse). The RT-PCR was performed using Superscript III
one-step RT-PCR systems with Platinum Taq (Invitrogen,
Carlsbad, California) under the following thermocycler conditions:
initial step of 94uC for 2 minutes, followed by 40 cycles of 94uC for
15 seconds, 60uC for 30 seconds, and 68uC for 1 minute, with a
final extension step of 68uC for 7 minutes. The 491-bp PCR
product was then purified and sequenced in both forward and
reverse directions using an ABI PRISM 3730XL Genetic Analyzer
(Applied Biosystems, Foster City, CA). Sequencing data were base-
called using sequencing analysis software and assembled and
analyzed with SeqScape software (Applied Biosystems) using
GenBank accession number NM 004972 as reference.
Figure 1. Schematic presentation of JAK2 Dexon 14. Top, schematic diagram of the JAK2 protein showing JAK homology domains 1 through 7
(JH1-JH7) with the JH2 pseudokinase domain highlighted in black. The corresponding exon regions of the mRNA is shown with the exons 13, 14, and
15. Because exon 14 is consists of 88 bp, its deletion leads to frameshift and early termination of translation after coding for seven new amino acids
and elimination of the V617 codon of JAK2 (lower panel). The resulting truncated JAK2 protein is shown on the bottom.
doi:10.1371/journal.pone.0012165.g001
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Length Analysis
Total nucleic acid was extracted as described above from
patient plasma or cells (peripheral blood or bone marrow). The
primer pair was designed to encompass JAK2 exon 14, with the
forward primer annealed in JAK2 exon 13 (59-GAC TAC GGT
CAA CTG CAT GAA A-39) and the reverse primer annealed in
exon 16 (59-CCATGCCAACTG TTTAGCAA-39). One of the
two primers was FAM-labeled. The RT-PCR was performed
using same buffer system (Invitrogen) and thermocycler conditions
as the sequencing method. The JAK2 wild-type and Dexon 14
products were verified by determining the size of PCR products
using the GeneScan 350ROX size standard (Applied Biosystems)
and ABI PRISM 3730XL Genetic Analyzer. The wild-type
product displays a 273-bp peak while the Dexon 14 splice variant
displays a 185-bp peak (ie, 273–88 bp). The percentage of
transcript accounted for by the JAK2 Dexon 14 splice mutant is
calculated using the following formula:
% Dexon 14=Total ~
Dexon 14 peak height 185bp ðÞ = Dexon 14 peak height 185bp ðÞ z ½




6) were lysed in isotonic lysis buffer (150 mM
NaCl, 20 mM Tris/HCl [pH 7.4], 0.3% Nonidet P-40, 12.5 mM b-
glycerophosphate, 2 mM NaF, 200 mMN a 3 V O 4 ,a n d1 m M
phenylmethylsulfonyl fluoride) containing 16 protease inhibitor
mix (Roche Applied Science, Indianapolis, IN). Clarified lysates
were subjected to immunoprecipitation using TrueBlot
TM beads
(Ebioscience, San Diego, CA) with an N-terminal anti-JAK2
antibody (JAK2-M126; Santa Cruz Biotechnology, Santa Cruz,
CA). After incubation at 4uCf o r4t o1 2h o u r s ,i m m u n ec o m p l e x e s
were washed 4 times in lysis buffer, separated by SDS/PAGE, and
analyzed by immunoblotting using C-terminal JAK2 antibody (JAK2
Figure 2. Detection of the JAK2 Dexon14 transcript with direct bi-directional sequencing. Upper panels: Detection of Dexon14 is relatively
easy when the transcript is present at high levels (eg, 29% of total JAK2 transcript). Detection is more difficult when the Dexon14 transcript makes up
a small proportion of total JAK2 transcript (eg, 6.9%). Normal control is shown on the bottom.
doi:10.1371/journal.pone.0012165.g002
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PLoS ONE | www.plosone.org 3 August 2010 | Volume 5 | Issue 8 | e12165Figure 3. JAK2 Dexon14 transcript as detected using RT-PCR with fragment length analysis. Lower panel: the expected 273-bp, full-length
amplification products; upper panel: the expected 273-bp, full-length wild-type peak in addition to a peak at 185 bp corresponding to the truncated
Dexon14 transcript. Size marker is shown as red peaks and amplification products are shown in blue.
doi:10.1371/journal.pone.0012165.g003
Figure 4. Source of RNA for detection of JAK2 Dexon14 transcript using RT-PCR with fragment length analysis. Similar results are
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JAK2 antibody (JAK2 N-17; Santa Cruz Biotechnology). K562 cell
line (ATCC CCL-243 Manassas VA) was used as negative control.
Immunoblot Analysis
Immunoblot analysis was performed as previously described
(Bruey et al, Leuk Res. 2009). Briefly, equal amounts of
immunoprecipitation products were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and the
gels were electrophoretically transferred to nitrocellulose mem-
branes (0.2-mm pore size; Whatman, Florham Park, NJ). The
blots were blocked with 5% bovine serum albumin in Tris-
buffered saline with 0.05% Tween-20 (TBS-Tween) for 2 hours.
The membrane was incubated with primary antibody for 5 hours
at 4uC, washed with TBS-Tween, and incubated with secondary
antibody for 30 minutes at room temperature (TrueBlot
TM,
Ebioscience). After additional washing in TBS-Tween, chemilu-
minescent reagent (ECL; GE Healthcare, Piscataway, NJ) was
added and the image was developed on x-ray film.
Results
Detection and Prevalence of JAK2 Dexon 14 Transcript
When JAK2 RNA (not DNA) is used for direct sequencing, the
Dexon 14 transcript is reliably detected if present at levels .15%
to 20% of total JAK2 RNA (Figure 1 and 2). MPN patients rarely
have Dexon 14 transcript levels above this threshold, and the
results of direct sequence analysis can be difficult to interpret in
patients with apparent low-level expression. In these cases, the
Dexon14 transcript can easily be interpreted as background or
poor sequencing if the background sequence is not read
completely and aligned to the JAK2 sequence (Figure 2). To more
accurately detect low levels of Dexon 14 transcript expression, we
developed an RT-PCR–based assay with fluorescent fragment
length analysis. With this method, the JAK2 Dexon14 splice
variant shows a 185-bp fragment while the wild-type shows a 273-
bp fragment (Figure 3). To confirm that the Dexon14 splice
variant that is detected in plasma is actually present in cells, we
analyzed paired cell and plasma RNA from patients previously
confirmed to show expression of the Dexon14 transcript in plasma.
Both plasma and cells revealed reliable results for detecting
Dexon14 transcripts (Figure 4).
Using the RT-PCR/fragment length analysis assay, we screened
all groups of patients. Samples with Dexon 14 mutant to wild-type
ratios greater than 15% by fragment analysis were tested and
successfully confirmed by careful inspection of direct sequencing
results. The Dexon14 was detected in 9 of the 61 confirmed MPN
patients (15%) (Table 1), where it accounted for 3.96% to 33.85%
(mean =12.04%) of JAK2 transcript. In this group of patients,
Dexon14 was detected in 33.3% of V617F-positive patients and in
57.9% of V617F-negative patients. This mutation was also
detected in 51 of the 183 patients with suspected MPNs (27%)
overall, including 20 of the 93 (22%) V617-positive patients (mean
[range] expression =5.41% [2.13%–26.22%]) and 31 of the 90
(34%) V617F-negative patients (mean expression =3.88%
[2.08%–12.22%]. While the difference in prevalence is not
statistically significant (P=0.07), there is a tendency of finding
Dexon14 in unmutated patients. None of the 46 plasma RNA
samples from the normal control group showed any expression of
the Dexon14 transcript. Most patients with Dexon14-positive in
each group had expression levels below 15%, therefore, it is
frequently missed by direct sequencing.
Effects of Dexon14 on JAK2 Protein
As indicated in Figure 1, deletion of exon 14 leads to a complete
deletion of codon V617, a hot spot for mutation in patients with
non-CML MPNs [3,4]. More importantly, since exon 14 is
composed of 88 bp, its deletion leads to a frameshift and the
coding of new amino acids. However, the frame shift results in the
addition of only 7 new amino acids, followed by a termination
codon leading to truncation of the JAK2 protein within the
pseudokinase domain. Therefore, we used immunoprecipitation
and immunoblotting to confirm that the truncated JAK2 protein is
expressed in cells from patients with confirmed JAK2 Dexon14
transcripts (Figure 5). Total JAK2 protein was immunoprecipitat-
ed using anti-JAK2 (N-terminal) antibody. For negative controls
we used the K562 CML cell line, which does not express JAK2
Dexon14, in addition to cell samples from 1) a patient with CML;
and 2) two patients with MPN who had been confirmed by RT/
PCR to be negative for Dexon14 transcripts. Cells from three
patients with different levels of Dexon14 transcript expression, as
confirmed by RT/PCR, were used as positive samples.
Probing with the anti-JAK2 N-terminal clone yielded a wild-
type JAK2 band at 130 kDa in the K562 and other negative
control lanes, and an additional band at 75 kDa only in patients
with confirmed expression of the Dexon14 transcript (Figure 5).
This additional immunoprecipitation product represents the
truncated JAK2 protein. The use of another anti-JAK2 clone
directed against the carboxyl-terminus of JAK2, which is deleted
from the truncated JAK2 protein, yielded a single band at
130 kDa, showing specificity of detection of the truncated JAK2
Dexon14 protein (Figure 5). Lysates from the K562 cell line and
the CML patient showed only the wild-type band at 130 kDa. This
confirms that the Dexon14 transcripts are translated.
Discussion
Our findings confirm that many individuals with non-CML
MPNs, especially those lacking V617F, express low levels of the
JAK2 Dexon14. The paucity of reports of the Dexon14 variant in
Table 1. Prevalence and Relative Level of the DExon14 JAK2 Transcript in Patients with Suspected or Confirmed Myeloproliferative
Neoplasms (MPNs)
Suspected MPN (n=183) Confirmed MPN (n=61)
V617F-Negative (n=90) V617F-Positive (n=93)
n( % )
Mean (range) percentage
of JAK2 transcript n (%)
Mean (range) percentage
of JAK2 transcript n (%)
Mean (range) percentage
of JAK2 transcript
Dexon14 31 (34) 3.88 (2.08–12.22) 20 (22) 5.41 (2.13–26.22) 9 (15) 12.04 (3.96–33.85)
No Dexon14 59 (66) NA 73 (78) NA 52 (85) NA
doi:10.1371/journal.pone.0012165.t001
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assays typically rely on DNA rather than RNA. Furthermore, this
abnormality cannot be detected with methods that rely on use of
specific probes. While bi-directional sequencing of mRNA
transcript can detect most mutations, including splice variants,
this approach lacks sensitivity (Figure 2). Therefore, a fluorescent
fragment analysis method such as the one describe here must be
used to detect low levels of this variant. The fact that the JAK2
Dexon14 transcript is a fraction of the total JAK2 transcript is,
most likely, due to either alternative splicing or a mutation in the
DNA in small fraction of the clone. Further studies are needed to
fully determine the mechanism of this phenomenon. We did not
sequence the DNA in cases with 100% JAK2 Dexon14 transcript
and the possibility of a mutation in the DNA in these patients is
likely and should be ruled out.
The fact that the JAK2 Dexon14 is detected only in patients with
MPNs, and more likely in patients negative for V617F (57.9% vs.
33.3%)(P=0.07), suggests that it may play a significant role in the
pathophysiology of MPNs. Current knowledge of JAK2 functional
domains and known mutations may shed light on the potential
biological effects of this unique splice variant. All currently
identified JAK2 mutations, including point mutations and indels in
exons 12 through 15, reside in the pseudokinase domain (JH2)-
coding region of JAK2 and do not affect the reading frame [5–7].
The JH2 domain is usually in close proximity to the kinase domain
(JH1), inhibiting its activation if not bound to an active receptor
[10–13]. Mutations in the JH2 domain may thus lead to
constitutive activation of the JAK2 protein; it is believed that
mutations in the JH2 domain cause constitutive activation in the
downstream JAK2-STAT signaling pathways as long as the JAK2
is bound to the receptor [14]. Deletion within the JH2 domain and
complete deletion of the kinase domain (JH1) is unexpected and
raises questions on its mechanism in activating the JAK2-STAT
pathway. The Dexon14 mutation preserves the JAK2 FERM
domain (JH4-7), which is responsible for association with growth
factor (eg, erythropoietin and thrombopoietin) receptors [15]. It is
thus possible that the truncated JAK2 dimerizes with wild-type
JAK2 to influence its structure, activating its kinase domain and
the JAK2-STAT pathway. It is also possible that the Dexon14
mutation causes activation of STAT5 by altering receptor binding
of the FERM domain. Clearly, further studies are needed to
understand the mechanism by which the truncated JAK2 is
involved in any activation of the JAK2-STAT pathway. Ex-vivo or
in-vivo experiments showing the effects of expressing JAK2
Dexon14 transcripts on tumorogenesis should be performed.
In conclusion, the JAK2 Dexon14 splice variant is a relatively
common anomaly in patients with MPNs, possibly more so in
those lacking the V617F mutation. Further functional analyses of
the Dexon14 JAK2 protein are needed to better understand how
this abnormality may contribute to the pathophysiology of disease
and its potential role as a marker for diagnosis, prognosis, or
prediction of response to therapy.
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Figure 5. Truncated JAK2 protein resulting from JAK2 Dexon14 mutation in patients with chronic myeloproliferative neoplasms.
Lysates were prepared from the indicated human CML K562 cell line (Lane1), a patient with chronic myelogenous leukemia (lane 2), and 5 patients
with chronic MPNs (Lanes 3–7). Patient 1: non-CML CMPD, JAK2 V617F positive; Patient 2: non-CML CMPD, JAK2 V617F negative; Patient 3: non-CML
CMPD, JAK2 Dexon14 positive; Patient 4: non-CML CMPD, JAK2 Dexon14 positive; Patient 5: non-CML CMPD, JAK2 Dexon14 positive. Top Panel:
Probing with an anti-JAK2 N-terminal clone yielded a wild-type JAK2 band at 130 kDa in the K562 and other negative control lanes, and an additional
band at 75 kDa only in patients with expression of Dexon14 transcript. Bottom Panel: An anti-JAK2 clone directed against the carboxyl-terminus of
JAK2 yielded only a single band at 130 kDa.
doi:10.1371/journal.pone.0012165.g005
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